FORTREA HOLDINGS DL-,001 Aktie Logo
US34965K1079
A3ECGB
FTRE

FORTREA HOLDINGS DL-,001 Aktie

Loading quotes...

Forecast

The analysts' average price target is €21.33 (+19.16%). The median is €21.38 (+19.44%).

Buy
  7
Hold
  5
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia

    Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » More on finanzen.net


  • Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business

    Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » More on finanzen.net


  • Fortrea buys early-phase unit from Worldwide for $45 million

    Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » More on de.investing.com


  • Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials

    Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » More on finanzen.net


  • Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials

    Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » More on de.investing.com

Financials

In the last quarter, FORTREA HOLDINGS DL-,001 Aktie had revenue of €610.49M and net profit of €529.71K
(EUR) September 2026
YoY
Revenue 610.49M 2.16%
Gross profit 123.16M 40.18%
Net profit 529.71K 103.91%
EBITDA 32.31M 180.88%

Fundamentals

Metric Value
Market capitalization
€1.69B
Number of shares
94.6M
52-week high/low
€23.80 - €7.78
Dividends No
Beta
1.86
P/E ratio
-25.99
PEG ratio
-0.11
P/B ratio
3.52
P/S ratio
0.69

Company profile

Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina.

Name
FORTREA HOLDINGS DL-,001 Aktie
CEO
Anshul Thakral
Headquarters Durham, nc
USA
Website
Industry
Health Care Equipment & Supplies
IPO
06/20/2023
Employees 14,000

Ticker symbols

Exchange Symbol
NASDAQ
FTRE
Frankfurt
K67.F
Düsseldorf
K67.DU
München
K67.MU
🍪

Parqet  uses cookies. Learn more